Acrobiosystems Co Ltd
SZSE:301080
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
31.53
66.85
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Acrobiosystems Co Ltd
Accounts Receivables
Acrobiosystems Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Acrobiosystems Co Ltd
SZSE:301080
|
Accounts Receivables
ÂĄ74.3m
|
CAGR 3-Years
33%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
||
Beigene Ltd
HKEX:6160
|
Accounts Receivables
ÂĄ2.5B
|
CAGR 3-Years
86%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Accounts Receivables
ÂĄ271m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accounts Receivables
ÂĄ3B
|
CAGR 3-Years
63%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Accounts Receivables
ÂĄ949.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
3%
|
CAGR 10-Years
25%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accounts Receivables
ÂĄ25.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
42%
|
CAGR 10-Years
50%
|
Acrobiosystems Co Ltd
Glance View
ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.
See Also
What is Acrobiosystems Co Ltd's Accounts Receivables?
Accounts Receivables
74.3m
CNY
Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Accounts Receivables amounts to 74.3m CNY.
What is Acrobiosystems Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
52%
Over the last year, the Accounts Receivables growth was 20%. The average annual Accounts Receivables growth rates for Acrobiosystems Co Ltd have been 33% over the past three years , 52% over the past five years .